Viatris Inc
VTRSAPI behind this page
VTRS Q3 2025 request
Playground key active
/api/financials?ticker=VTRS&year=2025&quarter=3
Pick an endpoint and run the request.
Income Statement
| Metric | Q3 2025 | Q3 2024 | YoY |
|---|---|---|---|
| Revenue | 3,747.5 | 3,738 | +0.3% |
Show Product Lines breakouts |
|||
| Amitiza ® | 40.8 | 38.2 | +6.8% |
| Brands | 2,436.8 | 2,362.2 | +3.2% |
| Brands · Developed Markets Segment | 1,241.3 | 1,217.6 | +1.9% |
| Brands · Emerging Markets Segment | 424.1 | 395.9 | +7.1% |
| Brands · Greater China | 612.3 | 559.4 | +9.5% |
| Brands · Japan, Australia and New Zealand Segment | 159.1 | 189.3 | -16.0% |
| Celebrex ® | 73.3 | 74.1 | -1.1% |
| Creon ® | 93.1 | 84.6 | +10.0% |
| Dymista ® | 33.8 | 43.5 | -22.3% |
| Effexor ® | 67.2 | 66.3 | +1.4% |
| EpiPen® Auto-Injectors | 157.2 | 123.2 | +27.6% |
| Generics | 1,310.7 | 1,375.8 | -4.7% |
| Generics · Developed Markets Segment | 1,014.3 | 1,081.1 | -6.2% |
| Generics · Emerging Markets Segment | 146.3 | 137.3 | +6.6% |
| Generics · Greater China | 2.9 | 2.4 | +20.8% |
| Generics · Japan, Australia and New Zealand Segment | 147.2 | 155 | -5.0% |
| Influvac ® | 125.4 | 121.3 | +3.4% |
| Lipitor | 396.1 | 375.6 | +5.5% |
| Lyrica ® | 126.5 | 129.9 | -2.6% |
| Norvasc | 179.7 | 168.9 | +6.4% |
| Viagra ® | 105.2 | 100.2 | +5.0% |
| Xalabrands | 38.6 | 41.2 | -6.3% |
| Xanax ® | 34.2 | 38.6 | -11.4% |
| Yupelri ® | 71.4 | 62.2 | +14.8% |
| Zoloft ® | 66.8 | 60.6 | +10.2% |
Show Business Segments breakouts |
|||
| Developed Markets Segment · Operating Segments | 2,255.6 | 2,298.7 | -1.9% |
| Emerging Markets Segment · Operating Segments | 570.4 | 533.2 | +7.0% |
| Greater China · Operating Segments | 615.2 | 561.8 | +9.5% |
| Japan, Australia and New Zealand Segment · Operating Segments | 306.3 | 344.3 | -11.0% |
| Other Revenue | 12.4 | 13.2 | -6.1% |
Show Product Lines breakouts |
|||
| Product And Service Other · Developed Markets Segment | 10 | 9.5 | +5.3% |
| Product And Service Other · Emerging Markets Segment | 1.4 | 2.1 | -33.3% |
| Product And Service Other · Japan, Australia and New Zealand Segment | 1 | 1.2 | -16.7% |
| Revenue | 3,759.9 | 3,751.2 | +0.2% |
Show Business Segments breakouts |
|||
| Developed Markets Segment | 2,265.6 | 2,308.2 | -1.8% |
| Emerging Markets Segment | 571.8 | 535.3 | +6.8% |
| Greater China | 615.2 | 562.2 | +9.4% |
| Japan, Australia and New Zealand Segment | 307.3 | 345.5 | -11.1% |
| Cost of Revenue | 2,388.4 | 2,292 | +4.2% |
| Gross Profit | 1,371.5 | 1,459.2 | -6.0% |
| Research & Development | 250.4 | 198.4 | +26.2% |
Show Consolidation Items breakouts |
|||
| Material Reconciling Items | 250.4 | 198.4 | +26.2% |
| Selling, General & Administrative | 886.6 | 1,003.4 | -11.6% |
| Gain Loss Related To Litigation Settlement | 55.7 | 31.5 | +76.8% |
Show Consolidation Items breakouts |
|||
| Material Reconciling Items | 55.7 | 31.5 | +76.8% |
| Operating Expenses | 1,192.7 | 1,233.3 | -3.3% |
| Operating Income | 178.8 | 225.9 | -20.8% |
Show Business Segments breakouts |
|||
| Developed Markets Segment · Operating Segments | 944.1 | 1,042.1 | -9.4% |
| Emerging Markets Segment · Operating Segments | 233.6 | 208.2 | +12.2% |
| Greater China · Operating Segments | 416.8 | 362.2 | +15.1% |
| Japan, Australia and New Zealand Segment · Operating Segments | 70.2 | 102.9 | -31.8% |
Show Consolidation Items breakouts |
|||
| Operating Segments | 1,664.7 | 1,715.4 | -3.0% |
| Interest Expense | 119.6 | 145.6 | -17.9% |
| Other Non-Operating Income (Expense) | 67.1 | -10.2 | +757.8% |
Show Disposal Group Classification breakouts |
|||
| OTC Business | -6.5 | -27.5 | +76.4% |
| Income Before Taxes | -7.9 | 90.5 | -108.7% |
| Income Tax Expense (Benefit) | 120.3 | -4.3 | +2897.7% |
| Net Income Loss Available To Common Stockholders Basic | -128.2 | 94.8 | -235.2% |
| EPS (Basic) | -0.11 | 0.08 | -237.5% |
| EPS (Diluted) | -0.11 | 0.08 | -237.5% |
| Wtd Avg Shares (Basic) | 1,164.6 | 1,193.5 | -2.4% |
| Wtd Avg Shares (Diluted) | 1,164.6 | 1,200.4 | -3.0% |
| Comprehensive Income | -177 | 383.7 | -146.1% |
| Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax (Q) | — | — | — |
Show Derivative Risk breakouts |
|||
| Foreign Exchange Contract · Cash Flow Hedging | 6.2 | -27.5 | +122.5% |
| Foreign Exchange Contract · Net Investment Hedging | 1.2 | -4.3 | +127.9% |
| Foreign Exchange Contract · Nondesignated | 18 | -168.4 | +110.7% |
| Interest Rate Swap · Cash Flow Hedging | -0.9 | -1.2 | +25.0% |
| Interest Rate Swap · Net Investment Hedging | 1.9 | -21.7 | +108.8% |
Balance Sheet
| Metric | Q3 2025 | Q3 2024 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash & Cash Equivalents | 975.3 | 1,878.7 | -48.1% |
| Accounts Receivable | 3,371.6 | 3,717.4 | -9.3% |
Show Accounts Notes Loans And Financing Receivable By Receivable Type breakouts |
|||
| Variable Consideration | 2,492.5 | 2,596.3 | -4.0% |
| Inventory | 4,111.4 | 4,084.6 | +0.7% |
| Prepaid Expenses & Other Current Assets | 1,493.1 | — | — |
| Total Current Assets | 9,951.4 | 11,307.7 | -12.0% |
| Non-Current Assets | |||
| Property, Plant & Equipment | 2,626.2 | 2,676.9 | -1.9% |
| Goodwill | 6,730.8 | — | — |
Show Business Segments breakouts |
|||
| Developed Markets Segment | 5,004.7 | — | — |
| Emerging Markets Segment | 797.1 | — | — |
| Greater China | 929 | — | — |
| Deferred Tax Assets | 999 | 763.1 | +30.9% |
| Other Non-Current Assets | 1,890.1 | 2,465.8 | -23.3% |
| Total Assets | 37,920.4 | 44,754.1 | -15.3% |
| Operating Lease Right-of-Use Assets | 265.9 | 267.6 | -0.6% |
| Intangible Assets | 14,945.1 | 17,087.3 | -12.5% |
| Other Assets | |||
| Intangible Assets Net Excluding Goodwill | 15,722.9 | 17,978.9 | -12.5% |
| Current Liabilities | |||
| Accounts Payable Trade Current | 1,793.4 | 1,925.9 | -6.9% |
| Current Portion of Long-Term Debt | 1,951.9 | 1,446.7 | +34.9% |
| Other Liabilities Current | 3,618.8 | 3,855.7 | -6.1% |
| Total Current Liabilities | 7,364.1 | 7,512.4 | -2.0% |
| Debt Current | 1,944.3 | — | — |
Show Debt Instrument breakouts |
|||
| Other Current Portion of Long-term Debt | 0.9 | — | — |
| YEN Term Loan | 270.4 | — | — |
| Non-Current Liabilities | |||
| Long-Term Debt | 12,487.6 | 14,303.4 | -12.7% |
Show Debt Instrument breakouts |
|||
| 2028 Euro Senior Notes · Senior Notes | 877.4 | 831.8 | +5.5% |
| 2028 Senior Notes [Member] · Senior Notes | 749.4 | 749.2 | 0.0% |
| 2043 Senior Notes (5.400% coupon) · Senior Notes | 497.6 | 497.5 | 0.0% |
| 2046 Senior Notes (5.250% coupon) · Senior Notes | 999.9 | 999.9 | 0.0% |
| 2048 Senior Notes [Member] · Senior Notes | 747.9 | 747.9 | 0.0% |
| Other Long Term Debt [Member] | 2.4 | 3 | -20.0% |
| Deferred Tax Liabilities | 1,028.2 | 1,276.6 | -19.5% |
| Other Non-Current Liabilities | 1,822.9 | 1,869.3 | -2.5% |
| Total Liabilities | 22,702.8 | 24,961.7 | -9.0% |
| Long-Term Debt (Q) | — | — | — |
Show Debt Instrument breakouts |
|||
| 2027 Euro Senior Notes · Net Investment Hedging | 850 | — | — |
| 2027 Euro Senior Notes · Senior Notes | 1,012.7 | — | — |
| 2027 Senior Notes · Senior Notes | 760 | — | — |
| 2028 Euro Senior Notes · Net Investment Hedging | 750 | — | — |
| 2030 Senior Notes · Senior Notes | 1,490.8 | — | — |
| 2032 Euro Senior Notes · Net Investment Hedging | 1,250 | — | — |
| 2032 Euro Senior Notes · Senior Notes | 1,550.6 | — | — |
| 2040 Senior Notes · Senior Notes | 1,631.9 | — | — |
| 2050 Senior Notes · Senior Notes | 2,188 | — | — |
| YEN Term Loan · Net Investment Hedging | 40,000 | — | — |
Show Derivative Instruments Gain Loss By Hedging Relationship breakouts |
|||
| Net Investment Hedging | 2,850 | — | — |
| Operating Lease Liabilities | 171.4 | 188.1 | -8.9% |
| Stockholders' Equity | |||
| Common Stock | 12.5 | 12.3 | +1.6% |
| Additional Paid-In Capital | 18,890.7 | 18,888.7 | 0.0% |
| Retained Earnings | -48.2 | — | — |
| Accumulated Other Comprehensive Income | -2,713.2 | — | — |
| Stockholders Equity Parent Before Treasury Stock | 16,141.8 | 20,296.7 | -20.5% |
| Treasury Stock Value | 924.2 | 504.3 | +83.3% |
| Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 15,217.6 | 19,792.4 | -23.1% |
Show Equity Components breakouts |
|||
| Accumulated Other Comprehensive Income | -2,713.2 | -2,686.3 | -1.0% |
| Additional Paid In Capital | 18,890.7 | 18,888.7 | 0.0% |
| Common Stock | 12.5 | 12.3 | +1.6% |
| Retained Earnings | -48.2 | 4,082 | -101.2% |
| Total Liabilities & Equity | 37,920.4 | 44,754.1 | -15.3% |
| Total Stockholders' Equity (Q) | — | — | — |
Show Equity Components breakouts |
|||
| Accumulated Defined Benefit Plans Adjustment | 250.4 | 262.5 | -4.6% |
| Accumulated Gain Loss Net Cash Flow Hedge Parent | -4.2 | -8.1 | +48.1% |
| Accumulated Net Unrealized Investment Gain Loss | -0.4 | -0.6 | +33.3% |
| Accumulated Other Comprehensive Income | -2,713.2 | -2,686.3 | -1.0% |
| Accumulated Translation Adjustment | -3,059 | -3,168.9 | +3.5% |
| Aoci Derivative Qualifying As Hedge Excluded Component Parent | 100 | 228.8 | -56.3% |
Cash Flow Statement
| Metric | YTD Q3 2025 | YTD Q3 2024 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Depreciation & Amortization | 2,031.5 | 2,147 | -5.4% |
| Stock-Based Compensation | 128.3 | 113.8 | +12.7% |
| Deferred Income Taxes | -228.3 | -518.7 | +56.0% |
| Gain Loss On Sale Of Business | 79.1 | 295.8 | -73.3% |
Show Disposal Group Classification breakouts |
|||
| Disposal Group Held For Sale Or Disposed Of By Sale Not Discontinued Operations · Other Nonoperating Income Expense | 79.1 | — | — |
| Payments To Acquire In Process Research And Development Other | 15 | -12.7 | +218.1% |
| Other Non-Cash Items | 835.8 | -180.6 | +562.8% |
| Changeinnoncashlitigationsettlementsnet | -45.1 | 245.6 | -118.4% |
| Change in Accounts Receivable | 62.7 | -0.4 | +15775.0% |
| Change in Inventory | -122.2 | -687.8 | +82.2% |
| Increase Decrease In Accounts Payable Trade | -186.5 | -9.7 | -1822.7% |
| Increase Decrease In Accrued Income Taxes Payable | -238.4 | 286.9 | -183.1% |
| Increase Decrease In Other Operating Capital Net | -593.8 | -62.3 | -853.1% |
| Net Cash from Operations | 1,500.1 | 1,820.2 | -17.6% |
| Investing Activities | |||
| Capital Expenditures | -182.3 | -185.6 | +1.8% |
| Payments To Acquire Marketable Securities | -18.1 | -21.7 | +16.6% |
| Proceeds From Sale And Maturity Of Marketable Securities | 18.1 | 21.7 | -16.6% |
| Other Investing Activities | -32.9 | -20.1 | -63.7% |
| Proceeds From Refund Of In Process Research And Development | -15 | 12.7 | -218.1% |
| Proceeds From Sale Of Productive Assets | 13.7 | 2.2 | +522.7% |
| Net Cash from Investing | -216.5 | 1,969.4 | -111.0% |
| Financing Activities | |||
| Share Repurchases | 415.4 | 250 | +66.2% |
| Proceeds From Repayments Of Short Term Debt | 1.7 | 1.5 | +13.3% |
| Tax Withholding for Share Compensation | -30.3 | -53.3 | +43.2% |
| Payments Of Merger Related Costs Financing Activities | -13.1 | -31.5 | +58.4% |
| Payments Of Financing Costs | -1.3 | -4.8 | +72.9% |
| Payments To Minority Shareholders | -423 | -431.5 | +2.0% |
| Proceeds From Issuance Of Common Stock | 2 | 1.9 | +5.3% |
| Proceeds From Payments For Other Financing Activities | -178.1 | 196.9 | -190.5% |
| Net Cash from Financing | -1,057.5 | -2,910.2 | +63.7% |
| Other Cash Flow | |||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 41.3 | 7.1 | +481.7% |
| Net Change in Cash | 267.4 | 886.5 | -69.8% |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 1,003.5 | 1,880.1 | -46.6% |
Values in millions USD. Source: SEC EDGAR 10-Q filing.